Vectura Group plc | Accessibility | Sitemap | Download centre

• Home
• Highlights
• Chairman and Chief Executive’s report
• Financial review
• Business review
  • Overview
  • Core purpose, strategy and values
  • Markets
  • Products
  • Enabling technologies
  • Capabilities
  • Key performance indicators
  • Risk management
  • Corporate governance statement
  • Board of Directors
  • Executive management
  • Corporate social responsibility statement
  • Report on remuneration
  • Directors’ report
• Financial statements
• Five-year summary
• Shareholder information

Board of Directors

John Patrick (Jack) Cashman
Non-Executive Chairman
Jack Cashman, aged 68, joined the Board of Vectura as Non-Executive Chairman in 2001 and is a member of both the Nomination and Remuneration Committees. Mr Cashman brings significant experience to the Board of Vectura, having held a variety of senior executive-level roles in business and having been a Board member for several companies in both North America and Europe. Jack is currently a Director of Transat AT Inc. (Canada) and a Director of Telesat Inc. (Canada). He is the former Chairman and joint-Chief Executive Officer of RP Scherer Corporation and participated in its leveraged buyout and privatisation and its subsequent successful flotation on the New York Stock Exchange. (RP Scherer was later acquired by Cardinal Health Inc.) His early career was spent in the field of filtration and industrial mineral products. During that time, he took on successively more senior roles in marketing, operations and general management in the UK, Europe, Canada and USA. With this experience, he decided to pursue an entrepreneurial career in the industrial and healthcare sectors.

Christopher Paul Blackwell BSc PhD
Chief Executive
Dr Chris Blackwell, 47, was appointed Chief Executive of Vectura in February 2004. He joined the Group in 2002 as Chief Operations Officer and Executive Director. Prior to Vectura he was Director of Drug Development and an Executive Director at Scotia Pharmaceuticals Ltd, which he joined in 1998. He was previously at Hoffmann-La Roche specialising in project management and becoming UK Director, Global Project Management, and Glaxo Research and Development as a Clinical Pharmacologist. Chris trained as a research scientist at the University of Bath, where in 1988 he completed his doctorate investigating free radicals and reperfusion-induced arrhythmias. In July 2006, Chris was appointed Non-Executive Director of AGI Therapeutics plc, a speciality pharmaceutical company focused on gastrointestinal drug products.

Anne Philomena Hyland BBS FCA FITI
Chief Financial Officer and Company Secretary
Anne Hyland, 48, was appointed Chief Financial Officer, Company Secretary and Executive Director of Vectura in March 2002. Prior to this she was a Director of Corporate Finance at Celltech Group plc. Other positions held at Celltech included Group Financial Controller and Finance Director for the Celltech/Medeva UK Division. She joined Celltech following the merger with Medeva plc, where she was Finance Director for the UK Division. Previously she was the Medeva Group Financial Controller where, through a period of rapid growth, she was responsible for managing treasury, tax, internal and external reporting, and acquisition and disposal activity. Anne joined Medeva from KPMG, London, where she was an audit manager and gained exposure to corporate finance, advisory and due diligence work. She has a Business Studies degree from Trinity College, Dublin, and is a Fellow of the Institute of Chartered Accountants, Ireland and a Fellow of the Institute of Taxation, Ireland.

John Robert Brown BSc PhD MBA FRSE
Non-Executive Director and Senior Independent Director
Dr John Brown, 54, joined the Board of Vectura as Non-Executive Director and Senior Independent Director in 2004 and chairs the Audit and Nomination Committees as well as being a member of the Remuneration Committee. He is Chairman of BTG plc and CXR Biosciences Ltd and is a Non-Executive Director of Axis-Shield plc. From 1999 until May 2008 John was Chairman of the Governing Council of the Roslin Institute in Edinburgh and is now Chairman of the Roslin Foundation. He is Chairman of BIA Scotland, a member of the UK Technology Strategy Board, and an advisor to several private equity and venture capital funds. Until late 2003, John was Chief Executive of Acambis plc, a leading producer of vaccines to treat and prevent infectious disease. John is an Honorary Professor of Edinburgh University and is a Fellow of the Royal Society of Edinburgh.

Susan Elizabeth Foden MA DPhil
Non-Executive Director
Dr Susan Foden, 56, joined the Board of Vectura as a Non-Executive Director in January 2007. She chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. She holds a number of Non-Executive Directorships with both public and private  companies and public funding bodies in the biotech and healthcare field, including Source Bioscience plc, Cell Centric Ltd, Cizzle Ltd, Rainbow Seed Fund Cascade Ltd, Oxford Ancestors Ltd, and is a Trustee of The Institute of Cancer Research. Prior to this Susan held positions in venture capital and UK biotech companies. From 2000 to 2003 she was an Investor Director with the London-based venture capital firm Merlin Biosciences Limited, and was Chief Executive Officer of the technology transfer company Cancer Research Campaign Technology Ltd from 1987 to 2000. She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.

Andrew John McGlashan Richards BA MA (Cantab) MSc PhD CChem
Non-Executive Director
Dr Andy Richards, 49, joined the Board of Vectura as a Non-Executive Director in 2000 and is a member of the Audit, Nomination and Remuneration Committees. He is an established biotechnology entrepreneur and business angel, focusing on founding, investing in and growing biotechnology and healthcare companies. He has broad experience of the UK biotechnology sector in research, drug development and in building commercial relationships. He is Chairman of Altacor Ltd and a Non-Executive Director of Aitua Ltd, Arecor Ltd, Biowisdom Ltd, Babraham Bioscience Technology Ltd, Cancer Research Technology Ltd (the commercial arm of Cancer Research UK), Theradeas Ltd and Summit Corporation plc. He is also a founder member of the Cambridge Angels, a director of the BIA (BioIndustry Association), a member of BBSRC Council and member of the UKTI Lifesciences strategy implementation board. In 1992, he co-founded Chiroscience and was Business Development Director through to its merger in 1999 with Celltech. Originally a protein chemist, Andy spent his early career with ICI (now AstraZeneca) and with PA Technology. Andy has a PhD in Chemistry.

©2009 Vectura Group plc Annual Report and Accounts 2008/09